Education
About Us
Working with TipRanks
Follow Us
Belite Bio, Inc. ADR (BLTE)
NASDAQ:BLTE
BLTE Stock Chart & Stats
Day’s Range― - ―
52-Week Range$31.01 - $86.53
Previous CloseN/A
Volume15.47K
Average Volume (3M)45.45K
Market Cap
$2.12B
Enterprise Value$1.33B
Total Cash (Recent Filing)$6.40M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.63
Next Earnings
May 07, 2025EPS Estimate
-0.35Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.18
Shares Outstanding32,281,760
10 Day Avg. Volume30,495
30 Day Avg. Volume45,450
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market Cap0.63
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-3.33K
Enterprise Value/Ebitda-36.30
Forecast
1Y Price Target
$96.67Price Target Upside44.93% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
---
Belite Bio, Inc. ADR News
PremiumCompany Announcements
Belite Bio, Inc. Appoints New Auditor
PremiumCompany Announcements
Belite Bio’s Earnings Call: Cautious Optimism Amid Progress---
Bulls Say, Bears Say
Bulls Say
Analyst RatingAnalyst reiterates Buy rating and $100 price target.
Financial PerformanceThe company raised $15M in a direct offering, adding to its cash reserves.
Regulatory ApprovalTinlarebant could potentially become the first FDA-approved treatment for Stargardt disease.
Bears Say
Clinical Study RisksThe overall discontinuation rate continues to be low (9.6%) with only 3.8% of discontinuations driven by the ocular AEs, which is encouraging.
Market RisksThe P3 PHOENIX Study in geographic atrophy continues to enroll, with the expectation of interim data by YE25, potentially being a significant long-term value driver for Belite.
---
Ownership Overview
7.30%
Insiders
0.02% Mutual Funds
0.53% Other Institutional Investors
92.07% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
BLTE FAQ
What was Belite Bio, Inc. ADR’s price range in the past 12 months?
Belite Bio, Inc. ADR lowest stock price was $31.00 and its highest was $86.53 in the past 12 months.
What is Belite Bio, Inc. ADR’s market cap?
Belite Bio, Inc. ADR’s market cap is $2.12B.
When is Belite Bio, Inc. ADR’s upcoming earnings report date?
Belite Bio, Inc. ADR’s upcoming earnings report date is May 07, 2025 which is in 36 days.
How were Belite Bio, Inc. ADR’s earnings last quarter?
Belite Bio, Inc. ADR released its earnings results on Mar 17, 2025. The company reported -$0.32 earnings per share for the quarter, missing the consensus estimate of -$0.308 by -$0.012.
Is Belite Bio, Inc. ADR overvalued?
According to Wall Street analysts Belite Bio, Inc. ADR’s price is currently Undervalued.
Does Belite Bio, Inc. ADR pay dividends?
Belite Bio, Inc. ADR does not currently pay dividends.
What is Belite Bio, Inc. ADR’s EPS estimate?
Belite Bio, Inc. ADR’s EPS estimate is -0.35.
How many shares outstanding does Belite Bio, Inc. ADR have?
Belite Bio, Inc. ADR has 32,281,760 shares outstanding.
What happened to Belite Bio, Inc. ADR’s price movement after its last earnings report?
Belite Bio, Inc. ADR reported an EPS of -$0.32 in its last earnings report, missing expectations of -$0.308. Following the earnings report the stock price went up 0.549%.
Which hedge fund is a major shareholder of Belite Bio, Inc. ADR?
Currently, no hedge funds are holding shares in BLTE
---
Belite Bio, Inc. ADR Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$96.67 (44.93% Upside)
$96.67 (44.93% Upside)
Blogger Sentiment
Bullish
BLTE Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 781.0 Shares
Last Quarter.
Last Quarter.
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
73.83%
12-Months-Change
Fundamentals
Return on Equity
-30.60%
Trailing 12-Months
Asset Growth
60.74%
Trailing 12-Months
Company Description
Belite Bio, Inc. ADR
Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery of vitamin A to the eye to reduce the accumulation of toxic vitamin A by-products in ocular tissue that is in phase 3 clinical trial. The company is also developing LBS-009, an anti-retinol binding protein 4 oral therapy targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, which is in the preclinical development phase. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.
---
BLTE Company Deck
---
BLTE Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented both positive and negative aspects. Significant advancements and regulatory designations for Tinlarebant, along with strong clinical trial enrollment and financial stability, were highlighted as major achievements. However, increased expenses, net loss, adverse events in trials, and high dropout rates were notable challenges. Despite the challenges, the overall sentiment was cautiously optimistic due to strong progress in clinical trials and financial stability.Read More>---
BLTE Stock 12 Month Forecast
Average Price Target
$96.67
▲(44.93% Upside)
Technical Analysis
Denali Therapeutics
―
Beam Therapeutics
―
Tarsus Pharmaceuticals
―
NewAmsterdam Pharma Company
―
Recursion Pharmaceuticals
―
Best Analysts Covering BLTE
1 Year
1 Year Success Rate
11/12 ratings generated profit
1 Year Average Return
+62.12%
reiterated a buy rating 7 days ago
Copying Bruce Jackson's trades and holding each position for 1 Year would result in 91.67% of your transactions generating a profit, with an average return of +62.12% per trade.
---